All In MedTech

FDA Clearance Tracker · P170024-S012

Surpass Elite Flow Diverter System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 18, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 18, 2024

Approved

Time to decision

383 days

Received May 1, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P170024-S012
Device name
Surpass Elite Flow Diverter System
Applicant location
Fremont, CA
Received
May 1, 2023
Decided
May 18, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P170024

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

the Surpass Elite Flow Diverter System that was developed through design modifications to the approved Surpass Evolve Flow Diverter System (P170024/S003). The design modifications consist of changes to the delivery system resheath pad and distal protection assembly, the stent braid to include a 5.25 mm diameter stent model and picks per inch specifications to be the same for all stent diameters, and manufacturing process for the stent braid and delivery system.

Source documents

Other decisions for Stryker Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.